409 related articles for article (PubMed ID: 15626576)
1. The preparation by extrusion/spheronization and the properties of pellets containing drugs, microcrystalline cellulose and glyceryl monostearate.
Chatchawalsaisin J; Podczeck F; Newton JM
Eur J Pharm Sci; 2005 Jan; 24(1):35-48. PubMed ID: 15626576
[TBL] [Abstract][Full Text] [Related]
2. New co-processed MCC-based excipient for fast release of low solubility drugs from pellets prepared by extrusion-spheronization.
Goyanes A; Martínez-Pacheco R
Drug Dev Ind Pharm; 2015 Mar; 41(3):362-8. PubMed ID: 24279425
[TBL] [Abstract][Full Text] [Related]
3. The influence of model drugs on the preparation of pellets by extrusion/spheronization: II. Spheronization parameters.
Tomer G; Podczeck F; Newton JM
Int J Pharm; 2002 Jan; 231(1):107-19. PubMed ID: 11719019
[TBL] [Abstract][Full Text] [Related]
4. The influence of chitosan and sodium alginate and formulation variables on the formation and drug release from pellets prepared by extrusion/spheronisation.
Chatchawalsaisin J; Podczeck F; Newton JM
Int J Pharm; 2004 May; 275(1-2):41-60. PubMed ID: 15081137
[TBL] [Abstract][Full Text] [Related]
5. The evaluation of formulations for the preparation of pellets with high drug loading by extrusion/spheronization.
Podczeck F; Knight P
Pharm Dev Technol; 2006; 11(3):263-74. PubMed ID: 16895837
[TBL] [Abstract][Full Text] [Related]
6. Influence of MCC II fraction and storage conditions on pellet properties.
Krueger C; Thommes M; Kleinebudde P
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1039-45. PubMed ID: 23872176
[TBL] [Abstract][Full Text] [Related]
7. The evaluation of modified microcrystalline cellulose for the preparation of pellets with high drug loading by extrusion/spheronization.
Podczeck F; Knight PE; Newton JM
Int J Pharm; 2008 Feb; 350(1-2):145-54. PubMed ID: 17905548
[TBL] [Abstract][Full Text] [Related]
8. Formulation of ranitidine pellets by extrusion-spheronization with little or no microcrystalline cellulose.
Basit AW; Newton JM; Lacey LF
Pharm Dev Technol; 1999; 4(4):499-505. PubMed ID: 10578503
[TBL] [Abstract][Full Text] [Related]
9. The preparation of pellets containing a surfactant or a mixture of mono- and di-gylcerides by extrusion/spheronization.
Newton JM; Pinto MR; Podczeck F
Eur J Pharm Sci; 2007 Mar; 30(3-4):333-42. PubMed ID: 17223021
[TBL] [Abstract][Full Text] [Related]
10. The influence of liquid binder on the liquid mobility and preparation of spherical granules by the process of extrusion/spheronization.
Boutell S; Newton JM; Bloor JR; Hayes G
Int J Pharm; 2002 May; 238(1-2):61-76. PubMed ID: 11996811
[TBL] [Abstract][Full Text] [Related]
11. The preparation of pellets containing non-ionic surfactants by extrusion/spheronization.
Podczeck F; Alessi P; Newton JM
Int J Pharm; 2008 Sep; 361(1-2):33-40. PubMed ID: 18571347
[TBL] [Abstract][Full Text] [Related]
12. Alternative extrusion-spheronization aids.
Jain SP; Singh PP; Amin PD
Drug Dev Ind Pharm; 2010 Nov; 36(11):1364-76. PubMed ID: 20521907
[TBL] [Abstract][Full Text] [Related]
13. Effect of lipid and cellulose based matrix former on the release of highly soluble drug from extruded/spheronized, sintered and compacted pellets.
Maboos M; Yousuf RI; Shoaib MH; Nasiri I; Hussain T; Ahmed HF; Iffat W
Lipids Health Dis; 2018 Jun; 17(1):136. PubMed ID: 29885655
[TBL] [Abstract][Full Text] [Related]
14. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
[TBL] [Abstract][Full Text] [Related]
15. Use of extrusion aids for successful production of Kollidon
Loka NC; Saripella KK; Pinto CA; Neau SH
Drug Dev Ind Pharm; 2018 Apr; 44(4):632-642. PubMed ID: 29183166
[TBL] [Abstract][Full Text] [Related]
16. Influence of Extrudate-Based Textural Properties on Pellet Molding Quality.
Tian W; Li X; Li W; Xue A; Zheng M; Lin X; Hong Y
Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895976
[TBL] [Abstract][Full Text] [Related]
17. Alginate-based pellets prepared by extrusion/spheronization: effect of the amount and type of sodium alginate and calcium salts.
Sriamornsak P; Nunthanid J; Luangtana-anan M; Weerapol Y; Puttipipatkhachorn S
Eur J Pharm Biopharm; 2008 May; 69(1):274-84. PubMed ID: 17962003
[TBL] [Abstract][Full Text] [Related]
18. Use of к-carrageenan, chitosan and Carbopol 974P in extruded and spheronized pellets that are devoid of MCC.
Valle BL; Omwancha WS; Neau SH; Wigent RJ
Drug Dev Ind Pharm; 2016 Nov; 42(11):1903-16. PubMed ID: 27100683
[TBL] [Abstract][Full Text] [Related]
19. Properties of microcrystalline cellulose and powder cellulose after extrusion/spheronization as studied by fourier transform Raman spectroscopy and environmental scanning electron microscopy.
Fechner PM; Wartewig S; Füting M; Heilmann A; Neubert RH; Kleinebudde P
AAPS PharmSci; 2003 Nov; 5(4):E31. PubMed ID: 15198519
[TBL] [Abstract][Full Text] [Related]
20. Use of kappa-carrageenan as alternative pelletisation aid to microcrystalline cellulose in extrusion/spheronisation. II. Influence of drug and filler type.
Thommes M; Kleinebudde P
Eur J Pharm Biopharm; 2006 May; 63(1):68-75. PubMed ID: 16325384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
